CN1316959C - Acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill and its preparing method - Google Patents
Acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill and its preparing method Download PDFInfo
- Publication number
- CN1316959C CN1316959C CN 200510051500 CN200510051500A CN1316959C CN 1316959 C CN1316959 C CN 1316959C CN 200510051500 CN200510051500 CN 200510051500 CN 200510051500 A CN200510051500 A CN 200510051500A CN 1316959 C CN1316959 C CN 1316959C
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- radix
- substrate
- mixed
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicine composition used for the treatment of weakness caused by the long periods of illnesses, sleeplessness, spontaneous perspiration, lassitude in the waist and leg, breath shortness, heart palpitation and other disorders, particularly an oral medicine composition preparation prepared from an extract containing the active medicinal components of acanthopanax root, angelica and astragalus as a raw material. The present invention has the purpose of complementing the deficiency of existing oral medicine preparations used for the treatment of the disorders, providing acanthopanax root-ginseng-angelica-astragalus dripping pills which is an oral medicinal composition preparation having high bioavailability, quick medicine release, rapid effect, high medicine content, accurate administration measurement, low price and convenient carrying. The acanthopanax root-ginseng-angelica-astragalus dripping pills of the present invention are prepared from an extract containing the active medicinal components of acanthopanax root, angelica, astragalus and other Chinese medicines as a raw material, and medicinal carriers serving as matrixes.
Description
Technical field
The present invention relates to a kind of strengthening the body resistance that has, invigorating QI to consolidate the body surface resistance, the blood-supplementing blood-nourishing effect, be used for valetudinarianism, the insomnia spontaneous perspiration, soreness of the waist and knees, the pharmaceutical composition of the treatment for diseases such as cardiopalmus of breathing hard is a kind of drug composition oral preparation that feedstock production forms with the extract that contains 3 flavor Chinese medicine active pharmaceutical ingredients such as Radix Et Caulis Acanthopanacis Senticosi, Radix Angelicae Sinensis, the Radix Astragali particularly.
Background technology
The acanthopanax bark-ginseng-Chinese angelica root-astragalus root essence that is prepared from according to the preparation method that provides among the drug standard WS3-B-0204-90 promulgated by the ministries or commissions of the Central Government, it is a kind of strengthening the body resistance that has, invigorating QI to consolidate the body surface resistance, the blood-supplementing blood-nourishing effect is used for valetudinarianism, the insomnia spontaneous perspiration, soreness of the waist and knees, the syrups oral formulations of the treatment for diseases such as cardiopalmus of breathing hard is through clinical verification, determined curative effect is the common drug that clinical and family is used for the treatment of this type of disease.Below be prescription and technology and the brief description that provides in the WS3-B-0204-90 drug standard:
Prescription: Radix Et Caulis Acanthopanacis Senticosi 200, Radix Angelicae Sinensis 100, the Radix Astragali 200
Method for making: above three flavors, Radix Et Caulis Acanthopanacis Senticosi decocts with water 4 times, each 1 hour, collecting decoction filters, and filtrate is concentrated into the thick paste shape, add the ethanol triplication, mixing is placed, filter, reclaim ethanol, add gelatin solution and do not produce to there being precipitation, add the ethanol quintuple again, placed 2 hours, filter, reclaim ethanol, be concentrated into the thick paste shape.The Radix Astragali, Radix Angelicae Sinensis decoct with water three times, and each 1 hour, collecting decoction filtered, and filtrate is concentrated into the thick paste shape, adds the ethanol triplication, and mixing is placed, and filters, and reclaims ethanol, carry out twice alcohol again and handle, and are concentrated into the thick paste shape; Add Mel, antiseptic, spice etc. to 1000ml, promptly.
Function cures mainly: strengthening the body resistance, and invigorating QI to consolidate the body surface resistance, blood-supplementing blood-nourishing is used for valetudinarianism, insomnia spontaneous perspiration, soreness of the waist and knees, the cardiopalmus of breathing hard.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.And the syrups oral formulations also exist medicament contg low, take metering and be difficult to accurately, take or carry shortcomings such as inconvenience.
In addition, conventional peroral dosage form as tablet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Summary of the invention
Purpose of the present invention, be to replenish the existing valetudinarianism that is used for, insomnia spontaneous perspiration, soreness of the waist and knees, the deficiency of the oral drug preparation of the treatment for diseases such as cardiopalmus of breathing hard, a kind of bioavailability height is provided, and has quick release, fast produce effects, the medicament contg height, take accurate measurement, cheap, and portable drug composition oral preparation acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill.
Acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill involved in the present invention is a raw material with the extract that contains 3 flavor Chinese medicine active pharmaceutical ingredients such as Radix Et Caulis Acanthopanacis Senticosi, Radix Angelicae Sinensis, the Radix Astragali, is prepared from the pharmaceutically suitable carrier as substrate.Be prepared by the following technical solutions, can obtain acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill involved in the present invention:
[preparation method]
1. the preparation of drug extract: with g or kg is unit, gets 2 parts of Radix Et Caulis Acanthopanacis Senticosis, 1 part of Radix Angelicae Sinensis, 2 parts of the Radixs Astragali, more than three flavors, Radix Et Caulis Acanthopanacis Senticosi decocts with water 4 times, each 1 hour, collecting decoction filtered, filtrate is concentrated into the thick paste shape; The Radix Astragali, Radix Angelicae Sinensis decoct with water three times, and each 1 hour, collecting decoction filtered, and filtrate is concentrated into the thick paste shape; Above-mentioned 2 kinds of thick pastes are merged, make evenly, continuing to be concentrated into relative density is 1.3～1.4 thick pastes, promptly; Perhaps continue to make drying under the same conditions, be ground into dry powder, promptly;
2. substrate: Polyethylene Glycol
(1000～20000), one or more the mixture in pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. according to the given ratio of prescription, accurately take by weighing drug extract and substrate, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing drug extract and substrate and/or emulsion and/or suspension;
5. adopt homemade or general drop pill machine (as the TZDW-1 type drop pill machine of Changzheng Tianmin High Science ﹠ Technology Co., Ltd., Beijing's production), and the temperature control system of adjustment drop pill machine, make the water dropper temperature heating of drop pill machine and remain on (50～90) ℃, the temperature cooling of condensing agent also remains on (40～-5) ℃;
6. when treating that the temperature of condensing agent in dropping-pill machine head and the condensation column is stable respectively and reaching desired state of temperature, fused solution and/or the emulsion and/or the suspension that will contain drug extract and substrate, place in the water dropper jar of drop pill machine, splash in the condensing agent, condensing agent can be any one in liquid paraffin, methyl-silicone oil, the vegetable oil;
7. will shrink the drop pill taking-up of molding by the outlet of drop pill machine, remove the surface condensation agent, be drying to obtain.Beneficial effect
The acanthopanax bark-ginseng-Chinese angelica root-astragalus root essence that is prepared from according to the preparation method that provides among the drug standard WS3-B-0204-90 promulgated by the ministries or commissions of the Central Government, it is a kind of strengthening the body resistance that has, invigorating QI to consolidate the body surface resistance, the blood-supplementing blood-nourishing effect is used for valetudinarianism, the insomnia spontaneous perspiration, soreness of the waist and knees, the syrups oral formulations of the treatment for diseases such as cardiopalmus of breathing hard is through clinical verification, determined curative effect is the common drug that clinical and family is used for the treatment of this type of disease.
Owing to reasons such as technologies of preparing, the oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.And the syrups oral formulations also exist medicament contg low, take metering and be difficult to accurately, take or carry shortcomings such as inconvenience.
In addition, conventional peroral dosage form as tablet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill involved in the present invention is compared with the acanthopanax bark-ginseng-Chinese angelica root-astragalus root essence has following beneficial effect:
1. acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill involved in the present invention; utilize surfactant to be substrate; make solid dispersion with the extract that contains 3 flavor active ingredient of Chinese herbs such as Radix Et Caulis Acanthopanacis Senticosi, Radix Angelicae Sinensis, the Radix Astragali; making medicine be molecule, colloid or microcrystalline state is scattered in the substrate; the total surface area of medicine increases; and substrate is hydrophilic; medicine had wetting action; can make medicine molten microgranule or the solution of loosing into rapidly; thereby make the dissolving of medicine and absorb quickening; thereby improved bioavailability, brought into play efficient, quick-acting effects etc.
2. acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill involved in the present invention, contact promptly with saliva and to dissolve rapidly, and absorb by oral mucosa, not only rapid-action, and the influence of not taken food, promptly all can containing take after meal ante cibum, can not produce any residual harmful substance at gastric yet, thereby make that patient's medication is safer, also have medication convenience, characteristic of accurate simultaneously.
3. acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill involved in the present invention mixes the extract that contains active constituents of medicine mutually with molten matrix, splashes in the not miscible condensed fluid and makes.Therefore, the stability of drug height, not facile hydrolysis, oxidation, and the operation be under liquid state, to carry out, no dust pollution is not subject to the influence of crystal formation, thereby has guaranteed the quality of medicine, has increased stability.
4. production technology, the equipment of preparation drop pill are simple, easy to operate, the automaticity height, and labor intensity is low, the production efficiency height.Workshop does not have dust simultaneously, helps labor protection and environmental protection yet.
5. the production cost of preparation drop pill is usually with about 50% of other oral formulations of kind, and compares with oral liquid, and the dosage of drop pill is accurate, thereby makes the patient take metering control easily.
The specific embodiment
Now with several groups of specific embodiments, be described further with regard to the preparation method of acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill of the present invention.
First group: the test of single-matrix
1. the preparation of drug extract: it is standby to make the extract dry powder that contains 3 flavor active ingredient of Chinese herbs such as Radix Et Caulis Acanthopanacis Senticosi, Radix Angelicae Sinensis, the Radix Astragali earlier according to [preparation method 1];
2. substrate: Polyethylene Glycol
(1000,2000,4000,6000,8000,10000,20000), one or more the mixture in pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. the process that provides according to [preparation method] 4～7 is prepared, and can obtain the acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill of different size.
[result of the test]
Test 1: for observe drug extract and different substrates when 1: 1 the proportioning prepared acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill in qualitative difference, according to 1: 1 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 1.
Test 2: for observe drug extract and different substrates when 1: 3 the proportioning prepared acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill in qualitative difference, according to 1: 3 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 2.
Test 3: for observe drug extract and different substrates when 1: 9 the proportioning prepared acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill in qualitative difference, according to 1: 9 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 15 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 3.
Second group: the test of mixed-matrix
1. the preparation of drug extract: it is standby to make the extract dry powder that contains 3 flavor active ingredient of Chinese herbs such as Radix Et Caulis Acanthopanacis Senticosi, Radix Angelicae Sinensis, the Radix Astragali earlier according to [preparation method 1];
2. substrate:
2.1 Polyethylene Glycol---English name Macrogol,
2.2 polyoxyethylene stearate 40 esters---English name Polyoxyl (40) Stearate,
Molecular formula is with C
17H
35COO (CH
2CH
2O)
nH represents that n is about 40,
2.3 poloxamer---English name Poloxamer, polyoxyethylene poly-oxygen propylene aether,
Molecular formula HO (C
2H
4O)
a(C
3H
6O)
b(C
2H
4O)
cH,
The sodium salt of the starch carboxymethyl ester that 2.4 carboxymethyl starch sodium---English name Carboxymethylstach Sodium, starch generates with the monoxone effect under alkali condition,
2.5 betacyclodextrin---English name Betacyclodextrin, molecular formula C
6H
10O
5, this product is that ring dextrin glucosyl transferase acts on 7 glucoses that starch generates with α-1, the bonded cyclic oligosaccharide of 4-glycosidic bond;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. the process that provides according to [preparation method] 4～7 is prepared, and can obtain the acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill of different size.
[result of the test]
Test 4: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 1 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 4.
Test 5: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 3 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 5.
Test 6: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 9 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 6.
Test 7: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 1 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 7.
Test 8: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 3 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 8.
Test 9: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 9 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 9.
Test 10: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill when 1: 1 proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 1 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 10.
Test 11: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill when 1: 3 proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 3 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 11.
Test 12: in order to observe the mass discrepancy of drug extract and mixed-matrix obtained acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill when 1: 9 proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 9 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experiments and the results are shown in Table 12.
The group practices of table 1 drug extract and single-matrix
(drug extract: substrate=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 50.0 | 54 | ＜30 | ＞10 | + |
| Polyethylene Glycol 2000 | 50.0 | 65 | ＜30 | ＞10 | + |
| Polyethylene Glycol 4000 | 50.0 | 75 | ＜30 | ＞10 | + |
| Polyethylene Glycol 6000 | 50.0 | 82 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 8000 | 50.0 | 83 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 10000 | 50.0 | 85 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 20000 | 50.0 | 85 | ＜30 | ＞10 | ++ |
| Polyoxyethylene stearate 40 esters | 50.0 | 75 | ＜30 | ＞10 | ++ |
| Betacyclodextrin | 50.0 | 72 | ＜30 | ＞10 | + |
| Poloxamer | 50.0 | 76 | ＜30 | ＞10 | ++ |
| Carboxymethyl starch sodium | 50.0 | 72 | ＜30 | ＞10 | + |
| Sodium lauryl sulphate | 50.0 | 68 | ＞30 | ＞10 | ++ |
| Stearic acid | 50.0 | 59 | ＞30 | ＞10 | ++ |
| Sodium stearate | 50.0 | 54 | ＞30 | ＞10 | ++ |
| Glycerin gelatine | 50.0 | 56 | ＞30 | ＞10 | + |
| Lac | 50.0 | 53 | ＞30 | ＞10 | + |
The group practices of table 2 drug extract and single-matrix
(drug extract: substrate=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 25.0 | 68 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 2000 | 25.0 | 78 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 4000 | 25.0 | 86 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 6000 | 25.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 8000 | 25.0 | 91 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 10000 | 25.0 | 91 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 20000 | 25.0 | 92 | ＜30 | ＜10 | +++ |
| Polyoxyethylene stearate 40 esters | 25.0 | 93 | ＜30 | ＜10 | ++ |
| Betacyclodextrin | 25.0 | 84 | ＜30 | ＞10 | ++ |
| Poloxamer | 25.0 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium | 25.0 | 87 | ＜30 | ＜10 | +++ |
| Sodium lauryl sulphate | 25.0 | 77 | ＜30 | ＞10 | ++ |
| Stearic acid | 25.0 | 74 | ＞30 | ＞10 | +++ |
| Sodium stearate | 25.0 | 72 | ＞30 | ＞10 | +++ |
| Glycerin gelatine | 25.0 | 70 | ＞30 | ＞10 | +++ |
| Lac | 25.0 | 70 | ＞30 | ＞10 | +++ |
The group practices of table 3 drug extract and single-matrix
(drug extract: substrate=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 10.0 | 73 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 2000 | 10.0 | 85 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 4000 | 10.0 | 88 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 6000 | 10.0 | 92 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 8000 | 10.0 | 93 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 10000 | 10.0 | 93 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 20000 | 10.0 | 93 | ＜30 | ＜10 | +++ |
| Polyoxyethylene stearate 40 esters | 10.0 | 88 | ＜30 | ＜10 | ++ |
| Betacyclodextrin | 10.0 | 87 | ＜30 | ＜10 | ++ |
| Poloxamer | 10.0 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium | 10.0 | 84 | ＜30 | ＞10 | +++ |
| Sodium lauryl sulphate | 10.0 | 83 | ＜30 | ＞10 | +++ |
| Stearic acid | 10.0 | 80 | ＞30 | ＞10 | +++ |
| Sodium stearate | 10.0 | 79 | ＞30 | ＞10 | +++ |
| Glycerin gelatine | 10.0 | 75 | ＞30 | ＞10 | +++ |
| Lac | 10.0 | 75 | ＞30 | ＞10 | +++ |
The group practices of table 4 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 50 | 84 | ＜30 | ＞10 | ++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 50 | 83 | ＜30 | ＞10 | ++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 50 | 78 | ＜30 | ＞10 | ++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 50 | 72 | ＜30 | ＞10 | + |
The group practices of table 5 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 25 | 90 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 25 | 89 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 25 | 86 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 25 | 83 | ＜30 | ＞10 | ++ |
The group practices of table 6 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 10 | 90 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 10 | 90 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 10 | 84 | ＜30 | ＞10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 10 | 84 | ＜30 | ＞10 | +++ |
The group practices of table 7 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 50 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 50 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 50 | 90 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 50 | 86 | ＜30 | ＜10 | ++ |
The group practices of table 8 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 25 | 93 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 25 | 93 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 25 | 92 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 25 | 88 | ＜30 | ＜10 | +++ |
The group practices of table 9 drug extract and mixed-matrix
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 10 | 93 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 10 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 10 | 92 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 10 | 89 | ＜30 | ＜10 | +++ |
The group practices of table 10 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 50 | 92 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 50 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 50 | 88 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 50 | 85 | ＜30 | ＞10 | +++ |
The group practices of table 11 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 25 | 92 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 25 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 25 | 89 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 25 | 87 | ＜30 | ＜10 | +++ |
The group practices of table 12 drug extract and mixed-matrix
(drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 10 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 10 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 10 | 92 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 10 | 90 | ＜30 | ＜10 | +++ |
1. can be seen by the result in the table: when the ratio of drug extract and substrate was 1: 1, its rounding rate, the ball method of double differences was different and index such as hardness is all undesirable, and dissolve scattered time limit influenced not obvious.
2. when the ratio of drug extract and substrate is 1: 3, the rounding rate, the ball method of double differences is different and index such as hardness slightly all begins to enter preferable state.
3. when the ratio of drug extract and substrate is 1: 9, the rounding rate, the ball method of double differences is different and index such as hardness improves not obvious.
4. the general effect of composite interstitial substance is better than single-matrix.
5. the hardness method for expressing in the subordinate list adopts drop pill is placed on the glass plate, press...withes one's finger it, observes its metamorphosis."+" expression flicking promptly is out of shape, " ++ " expression distortion of firmly pressing, and " +++" expression is indeformable by it.
Claims (2)
- One kind treat valetudinarianism, the oral drop pills of the cardiopalmus of breathing hard, be raw material with Radix Et Caulis Acanthopanacis Senticosi, Radix Angelicae Sinensis, the Radix Astragali, be prepared from pharmaceutically suitable carrier as substrate, it is characterized in that:(1) according to the weight portion meter, get 2 parts of Radix Et Caulis Acanthopanacis Senticosis, 1 part of Radix Angelicae Sinensis, 2 parts of the Radixs Astragali, more than three flavors, Radix Et Caulis Acanthopanacis Senticosi decocts with water 4 times, each 1 hour, collecting decoction filtered, filtrate is concentrated into the thick paste shape; The Radix Astragali, Radix Angelicae Sinensis decoct with water three times, and each 1 hour, collecting decoction filtered, and filtrate is concentrated into the thick paste shape; Above-mentioned 2 kinds of thick pastes are merged, make evenly, continuing to be concentrated into relative density is 1.3～1.4 thick pastes, promptly; Perhaps continue to make drying under the same conditions, be ground into dry powder, promptly get the extract that contains Radix Et Caulis Acanthopanacis Senticosi, Radix Angelicae Sinensis, Radix Astragali effective ingredient, standby;(2) described substrate is the mixture of Polyethylene Glycol and polyoxyethylene stearate 40 esters or carboxymethyl starch sodium, by weight, the mixed proportion of polyoxyethylene stearate 40 esters or carboxymethyl starch sodium and Polyethylene Glycol is 1: 1～1: 10, and the ratio of described extract and substrate is 1: 3;(3) according to aforementioned proportion, accurately take by weighing described extract and substrate, be placed on heating while stirring in the heating container, until the fused solution that obtains containing described extract and substrate, or emulsion, or suspension, standby;(4) temperature control system of adjustment drop pill machine makes the water dropper heating of drop pill machine and maintains the temperature at 50 ℃～90 ℃, and the condensing agent cooling also maintains the temperature at 40 ℃～-5 ℃;When (5) treating that dropping-pill machine head and condensing agent are stable respectively and reach described state of temperature, will contain the fused solution of described extract and substrate, or emulsion, or suspension, place in the water dropper jar of drop pill machine, splash in the condensing agent and shrink molding promptly.
- 2. oral drop pills as claimed in claim 1 is characterized in that: described condensing agent be methyl-silicone oil or/and liquid paraffin or/and vegetable oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510051500 CN1316959C (en) | 2005-03-08 | 2005-03-08 | Acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510051500 CN1316959C (en) | 2005-03-08 | 2005-03-08 | Acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682925A CN1682925A (en) | 2005-10-19 |
| CN1316959C true CN1316959C (en) | 2007-05-23 |
Family
ID=35262544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510051500 Expired - Fee Related CN1316959C (en) | 2005-03-08 | 2005-03-08 | Acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1316959C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109276591B (en) * | 2018-11-28 | 2021-08-10 | 吉林修正药业新药开发有限公司 | New application of acanthopanax, angelica and astragalus composition in assisting in reducing blood sugar |
| CN113332388A (en) * | 2021-06-10 | 2021-09-03 | 深圳市璐琥实业发展有限公司 | Essential oil for soothing nerves and helping sleep and using method |
-
2005
- 2005-03-08 CN CN 200510051500 patent/CN1316959C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1682925A (en) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1660368A (en) | Oral drop pill in use for clearing away heat and toxic material and preparation method | |
| CN1686478A (en) | Cough suppressing phlegm transforming drip pill and its preparation method | |
| CN1682923A (en) | Body strengthening dripping pill for invigorating qi and refreshing and its preparing method | |
| CN100341489C (en) | Xianling gubao dripping pills having functions of reinforcing kidney strengthening bone, and its prepn method | |
| CN100341487C (en) | 'Shuanghuang' antiphlogistic drop pill in use relieving inflammation and preparation method | |
| CN1316959C (en) | Acanthopanax bark-ginseng-Chinese angelica root-astragalus root dripping pill and its preparing method | |
| CN1682918A (en) | Tranquilizing wild jujube seed dripping pill and its preparing method | |
| CN1307980C (en) | Lemai dripping pill for treating cardiovascular diseases and its preparing method | |
| CN1292741C (en) | Ginseng and schisandra fruit dripping pill and its preparing method | |
| CN100344314C (en) | Xinnaoshu dripping pill for invigorating qi and nourishing yin and its preparing method | |
| CN1292737C (en) | Oral administration dripping pill for nourishing heart to calm mind and its preparing method | |
| CN1316962C (en) | Cough panting quieting drip pill and its preparation method | |
| CN1292738C (en) | Ginseng-pilose antler dripping pill for tonifying heart and kidney and its preparing method | |
| CN1682806A (en) | Ginseng and fleece-flower root dripping pill and its preparing method | |
| CN1317010C (en) | Huoliguan dripping pill for tonifying heart and kidney and its preparing method | |
| CN1307983C (en) | Mai-an dripping pill for treating hyperlipoproteinemia and its preparing method | |
| CN1682920A (en) | Anshenning dripping pill for treating neurosism and its preparing method | |
| CN1686339A (en) | Compound cynomorium drip pill and its preparation method | |
| CN1686340A (en) | Gastrodia brain arousing drip pill for nourishing liver and kidney and its preparation method | |
| CN1686453A (en) | Child cough panting drip pill and its preparation method | |
| CN1292740C (en) | Ginseng and Chinese angelica root dripping pill and its preparing method | |
| CN1686518A (en) | Ganoderma astragalus drip pill for treating heart spleen vacuity and its preparation method | |
| CN1686346A (en) | Danxiyupingfeng drip pill and its preparation method | |
| CN1660366A (en) | Notoginseng floral leaf drop pill in use for cleaning away heat and its prepn. process | |
| CN1698783A (en) | Dripping pills of emblic leafflower fruit and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070523 |